Back to search

Article

Human Mesenchymal Stem Cells Treatment for Severe COVID-19: 1-Year Follow-Up Results of a Randomized, Double-Blind, Placebo-Controlled Trial

2021-07-28

Abstract excerpt

Background The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial.<br><br>Methods: In this prospective, longitudinal, cohort study, 100 patients enrolled in our phase 2 trial were prospectively f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
149ad094-ff3f-5a97-b06e-25f01b53f603
DOI
10.2139/ssrn.3894960
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Human Mesenchymal Stem Cells Treatment for Severe COVID-19: 1-Year Follow-Up Results of a Randomized, Double-Blind, Placebo-Controlled TrialDOI 10.2139/ssrn.3894960
Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in COVID-19 Patients: A Phase 1 Clinical TrialSemantic proximity
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot studySemantic proximity
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trialSemantic proximity
Effectiveness and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-AnalysisSemantic proximity
The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 PatientsSemantic proximity
The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expectSemantic proximity
Mesenchymal Stem Cells in the Treatment of COVID-19, a Promising Future.Semantic proximity
Respiratory outcomes after six months of hospital discharge in patients affected by COVID-19: a prospective cohortSemantic proximity
Investigating phenotypes of pulmonary COVID-19 recovery – a longitudinal observational prospective multicenter trialSemantic proximity
Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and FibrosisSemantic proximity
Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the ScienceSemantic proximity
Mesenchymal Stem Cells Impact on COVID-19 Patients Immune System, an Ex Vivo StudySemantic proximity
Select a neighboring publication to make it the new centre.